No Detail Found!

Comparison of Suprachoroidal Triamcinolone Injection with Intravitreal Bevacizumab Vs Intravitreal Bevacizumab only in Treatment of Refractory Diabetic Macular Edema

Author(s)
MUHAMMAD HAMZA SHAHID Department of Ophthalmology, Services Hospital,Jail Road, Lahore,Pakistan
FAISAL RASHID SIMS/Services Hospital Lahore,Pakistan
SABA TAUQEER Department of Ophthalmology, Services Hospital Lahore,Pakistan
RABAB ALI Services Hospital Lahore,Pakistan
MUHAMMAD TALHA FAROOQ SIMS/ Services Hospital Lahore,Pakistan
NOUMAN ALEEM SIMS/Services Hospital Lahore,Pakistan
Abstract
Background: Macular edema due to diabetic retinopathy is among the most common causes of blindness in diabetics from working age group around the world . Diabetic macular edema which involves the center of the macula is among the major cause of visual decline in patients with diabetes mellitus. Intra-Vitreal Triamcinolone Acetonide with intravitreal Bevacizumab and intravitreal Bevacizumab only have been in practice as treatment options for cases not responsive to anti-vascular endothelial growth factor agents. Objective: To compare safety and efficacy profile of suprachoroidal injection of triamcinolone acetonide with intravitreal Bevacizumav Vs intravitreal injection of Bevacizumab alone in management of resistant diabetic macular edema. Patients & Methods: In this study, Fourty eyes of fourty patients who had resistant diabetic macular edema were randomly divided into two groups of 20 patients each (n=20) , our group A was injected with suprachoroidal triamcinolone acetonide 2 mg along with intravitreal Bevacizumab 1.25mg and the group B wasinjected with intravitreal Bevacizumab 1.25 mg only. Change in central macular thickness was observed after one month on Optical coherence tomography. Data was collected and analyzed by using SPSS software. Results: The mean age of subjects in this study was 58.46±3.62 years ( 30-65 years) . Out of 40 patients 26 were male patients and 14 were female .The mean decline (change) in central macular thickness in comparison to baseline thickness on OCT in group A was 113±10microns and mean change in the central thickness of macula on OCT in group B was 83+-10 microns with a p value of 0.01. Conclusion: Suprachoroidal triamcinolone acetonide with intravitreal bevacizumab is superior to intravitreal Bevacizumab alone in reducing central macular thickness among patients with resistant diabetic macular edema.
Publication Details
Page(s) 301-303
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 16, Issue: 06, Year: 2022

Request the full text from PASTIC

Keywords
macular edema, optical coherence tomography, Intravitreal bevacizumab, Suprachoroidal Triamcinolone
References
Hinai Al,Wali A.,Rasool T. A.,Rizvi S. G. .2017 .Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population. Oman J Ophthalmol, 10 : 177-183.
R. .2019 .Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. , 321 : 1880-1894.
Bressler S. B.,Odia I.,Glassman A. R.,Grover R. P.,S. R. P.,G. R. R. P.,Maguire L. M.,Melia M. G.,M. M. G. .2018 .. , : .
Report Year . .Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.net Protocol I 5. , 38 : 1896-1904.
Retinopathy Clinical Research Diabetic,N. Diabetic .2008 .A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid 5. , : .
. .photocoagulation for diabetic macular edema. Ophthalmology, 115 : 1447-145010.
R. ,Bressler L. P.,Ferris N. M.,Glassman F.,Hartnett A. R.,Ip E.,Kim M. S.,Kollman J. E.,C. J. E. .1960 .Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of ophthalmology (Chicago, 127 : 245-251.
Distefano L. N.,Garcia-Arumi J.,Martinez-Castillo V.,Boixadera A. .2017 .Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review. Journal of ophthalmology, : 2407037-2407037.
Ghoraba H. H.,Elgouhary M.,Elgemai S. M.,Abdelfattah E. E. M.,Ghoraba H. M.,Heikal H. H.,M. A. H. H. .2018 .Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middleincome countries. Clin Ophthalmol, 12 : 2383-2391.
Habot-Wilner Z.,Noronha G.,Wykoff C. C. .2019 .. , : .
. .Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta ophthalmologica, 97 : 460-472.
Tayyab; Chaudhry Nasir Ahmed; M. Ali Ayaz Sadiq Haroon .2020 .. , : .
. .Efficacy and safety of Suprachoroidal Triamcinolone Acetonide in cases of resistant diabetic Macular Edema. Pakistan journal of medical sciences, Jan-Feb; 36(2), : 42-47.
Romero-Aroca P.,Reyes-Torres J.,Baget-Bernaldiz M.,BlascoSuñe C. .2014 .Laser treatment for diabetic macular edema in the 21st. century. Current diabetes reviews, 10 : 100-112.
Villegas V. M.,Schwartz S. G. .2018 .Current and Future Pharmacologic Therapies for Diabetic Retinopathy. Curr Pharm Des, 24 : 4903-4910.
Wykoff CC,Khurana RN,Lampen SIR,Noronha G,Brown DM,HULK StudyGroup DM .2018 .Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema:The HULK Trial. , : .
Bakbak B,Ozturk BT,Gonul S,Gedik S. .2016 .The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs. Oman journal of ophthalmology, 9(1) : 44.
Ishibashi T,Li X,Koh A,Lai TY,Lee F-L,Lee W-K F-L .2015 .The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology, 122(7) : 1402-15.
Sarhan A-RE,Mandour SS,Zayed AZ .2019 .Evaluation of intravitreal injection of ranibizumab in diabetic macular edema. Menoufia Medical Journal, 32(4) : 1447.
Hall L,Frizzera LP,Coelho LF,Carricondo PC,Oyamada MK,Pimentel SLG .2019 .Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion. International journal of retina and vitreous, 5(1) : 32.
Kaya M,Karahan E,Ozturk T,Kocak N,Kaynak S. .2018 .Effectiveness of intravitreal ranibizumab for diabetic macular edema with serous retinal detachment. Korean Journal of Ophthalmology, 32(4) : 296-302.
Schechet SA,Adams OE,Eichenbaum DA,Hariprasad SM .2019 .Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema. BMJ open ophthalmology, 4(1) : e000271.
0

Citations

0

Downloads

116

Views